How to align stakeholders before a life sciences website redesign

Every life sciences website redesign carries a quiet risk that has nothing to do with design. The scientific team, the commercial team, and the regulatory and legal reviewers each arrive with a different picture of what the site is for, and none of them is wrong. The problem is that those pictures only collide once comps are on the table, when a change costs far more than it would have in a conversation. We align the people before we align the pixels, because that is where redesigns are won or lost.

Why alignment comes before design

In most industries a website serves one primary audience and one buying motion. A life sciences organization rarely has that luxury. The same homepage is read by a principal investigator evaluating scientific credibility, a procurement lead comparing suppliers, an investor scanning the pipeline, and a reviewer checking that nothing on the page oversteps a claim. When those readers are not reconciled up front, the redesign becomes a negotiation conducted through revisions, and the timeline absorbs the cost.

Alignment is not a kickoff formality. It is the decision log that lets the build proceed without relitigating scope every week. Our aim before design starts is simple. Every person who can halt the project should recognize their priorities in a written brief and should have agreed, in advance, on how competing priorities get resolved.

Map the people who hold a veto

Start by naming who can stop the work, not who attends the meetings. On a life sciences redesign that list usually includes more than the marketing sponsor who holds the budget.

• Scientific and medical leadership, who protect accuracy and will not sign off on language that softens the evidence.
• Commercial and sales leadership, who need the site to generate and qualify demand.
• Regulatory, legal, and medical review, who govern claims, fair balance, and anything that touches a product indication.
• IT and security, who own hosting, data handling, and the vendor review that approves the platform.
• Investor relations or corporate communications, where a public company has disclosure obligations tied to pipeline and data.

Each of these functions has a legitimate claim on the outcome. Naming them early turns a late surprise into a planned input.

Agree on what the site is for

Once the people are named, force a single decision that everything else hangs from. What is the primary job of this life sciences website, and what is it willing to be second-best at. A site cannot be the definitive scientific reference, the highest-converting commercial funnel, and the investor showcase all at equal weight. The homepage can serve several audiences, but the architecture has to privilege one path.

We run this as a ranking exercise rather than an open discussion, because ranking produces a decision and discussion produces minutes. When the scientific audience ranks first, the information architecture leads with evidence and the commercial calls to action ride alongside it. When the commercial motion ranks first, the evidence becomes the proof that supports a conversion path. Either is defensible. What is not defensible is leaving the question open and discovering the answer in round three of comps.

Write down the decisions that will stall you later

Certain questions resurface in every life science website redesign, always at the worst moment. Resolve them in writing before design, and attach a named owner to each.

1. Claims and review. Who approves product and efficacy language, and how long does a review cycle take. This single number reshapes the content calendar.
2. Data and privacy. What personal data the site collects, where it lives, and which consent and tracking rules apply across the regions you serve.
3. Accessibility. The conformance target, which for most organizations is WCAG 2.1 AA, agreed as a requirement rather than a nice-to-have.
4. Content ownership. Who writes, who reviews, and who has final sign-off, mapped per section so the pipeline and publications pages do not orphan.
5. Brand and voice. How much the scientific register and the commercial register are allowed to differ on the same site.

A decision log that answers these is worth more than any mood board at this stage. It is the artifact a reviewer can point to when a disagreement flares, and it keeps the project honest.

Carry alignment into the build

Alignment decays if it lives only in a kickoff deck. The decisions have to travel into the audit, the architecture, and the wireframes as constraints the team designs against. This is why the work that comes next depends on getting this right. The audit that opens a redesign inherits these priorities as its lens, and the choices about structuring the site for scientific and commercial audiences are only possible once the ranking exercise has produced an answer.

We are platform agnostic front- and back-end technologists, enabling enterprise-scale web transformation for regulated organizations, and the pattern holds across every engagement. The redesigns that run clean are the ones where the hard conversations happened before design, not during it. Our work with partners such as Taconic Biosciences and CLSI started the same way, with a brief that every veto-holder recognized as their own.

If you are weighing a redesign and want a clearer sense of how a specialist partner approaches this phase, what to expect from a life science marketing agency covers the ground in more detail.